Detalhe da pesquisa
1.
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Target Oncol
; 10(2): 235-45, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25077897
2.
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Mol Cancer Ther
; 14(11): 2422-32, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26271675
3.
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Mol Cancer Ther
; 13(2): 353-63, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24398428
4.
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Clin Cancer Res
; 20(2): 413-24, 2014 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24173541
5.
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Mol Cancer Res
; 12(7): 1042-54, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24784839
6.
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Cancer Discov
; 3(4): 430-43, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23533265
7.
Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer.
Clin Cancer Res
; 18(18): 4973-85, 2012 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22806877